Weight-Loss Drugs Could Treat Fatal Heart Attack Complications, UK Study Finds
Groundbreaking research has discovered that weight-loss medications like Ozempic and Wegovy could assist heart attack patients in avoiding potentially fatal complications during recovery. The latest findings, based on animal model trials, indicate that GLP-1 drugs may prevent the common problem of 'no-reflow', which affects up to half of the 100,000 individuals in the UK who suffer a heart attack annually.
Promising New Therapeutic Approach
Experts in heart health have concluded that GLP-1 weight-loss drugs could offer a promising new therapeutic approach for improving heart attack recovery. While these drugs are already known to lower the risk of heart attacks or strokes, this marks the first time they have been repurposed to address this specific complication. Dr Svetlana Mastitskaya, the study's lead author and a senior lecturer at Bristol University's medical school, explained the significance of the results.
In nearly half of all heart attack patients, tiny blood vessels within the heart remain narrowed, even after the main artery is cleared during emergency treatment, said Mastitskaya. This results in a complication known as 'no-reflow', where blood is unable to reach certain parts of the heart tissue.
Potential Life-Saving Solution
No-reflow increases the risk of death or hospital readmission for heart failure within a year post-heart attack. However, the study's findings are surprising, as GLP-1 drugs may prevent this issue. Professor David Attwell of University College London, a co-lead of the study, described GLP-1s as a potentially life-saving solution for those experiencing no-reflow.
Mastitskaya highlighted the practical implications, noting that the drugs can be given by paramedics attending the patient even on the way to the hospital and/or during surgical reopening of the occluded artery. She emphasised that clinical trials are necessary before implementation.
Need for Further Research
The results, published in Nature Communications and funded by the British Heart Foundation, are based on animal model trials. Further studies involving humans are required to confirm the benefits before GLP-1s can be used clinically. Professor Bryan Williams, the BHF's chief scientific and medical officer, commented on the research's implications.
This research suggests that mimicking the action of the GLP-1 hormone may have potential to improve blood flow through microvessels and perhaps one day could have a role in heart attack treatment, said Williams. This will require detailed studies in humans and clinical trials first.
He added that large clinical trials of GLP-1 medicines have shown heart health benefits beyond weight loss, but the mechanisms remained unclear. This study offers one possible explanation, indicating they may help improve blood flow through the heart's smallest blood vessels.
